Accelrys Releases New Cheminformatics Software; Software Toolkit for Creating Web-Based Cheminformatics Applications.

SAN DIEGO -- Accelrys Inc. (NASDAQ:ACCL) today announced the release of the Accord(TM) Enterprise (AE) Webkit(TM), its latest software solution for chemical and biological information management.

The AE Webkit enables users to build and customize their own cheminformatics applications using commercial quality, validated components to create Web browser-based user interfaces to deploy such applications. In addition to the lower cost of deployment, browser-based applications are flexible, easily tailored to specific groups of users and simple to learn and use. This is the first in a series of Webkit releases.

AE Webkit makes full use of the power of the Accord Enterprise Informatics (AEI) system to store, search and retrieve chemical structures, and structure-related and biological data, along with tools and components that perform essential tasks in chemical analysis or programming. AEI empowers multi-disciplinary scientific functions in pharmaceutical and biotechnology organizations.

"The Accord Enterprise Webkit delivers an innovative collection of tools that enable researchers and informaticians to flexibly tailor their access to chemical information within their enterprise environment," said Dr. Scott Kahn, chief science officer, Accelrys. "Improved access to project data through customized Web-based applications will enable better use of investments in new science."

About Accelrys Inc.

Accelrys Inc. (NASDAQ:ACCL) is the parent of Accelrys Software Inc., a leading provider of software for computation, simulation and the management and mining of scientific data used by biologists, chemists and materials scientists, including nanotechnology researchers for product design as well as drug discovery and development. Accelrys technology and services are designed to meet the needs of today's leading research organizations. The company is headquartered in San Diego. For more information about Accelrys, visit its Web site at http://www.accelrys.com/.

When used anywhere in this document, the words expects, believes, anticipates, estimates and similar expressions are intended to identify forward-looking statements. Forward-looking statements herein may include statements addressing future financial and operating results of Accelrys. Accelrys has based these forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of Accelrys' strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of existing and potential future patent issues, additional competition, changes in economic conditions and other risks described in documents Accelrys has filed with the Securities and Exchange Commission, including its most recent report on Form 10-K and subsequent reports on Form 10-Q. All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Accelrys disclaims any undertaking to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.